Recent News

• 03.30.2026 - Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
• 03.23.2026 - Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
• 03.17.2026 - Royalty Pharma Announces Expansion of Leadership Team
• 03.02.2026 - Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma’s Global Platform
• 03.02.2026 - Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
• 02.26.2026 - Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference

Recent Filings

• 03.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.23.2026 - 144 Report of proposed sale of securities
• 03.19.2026 - 144 Report of proposed sale of securities
• 03.18.2026 - 144 Report of proposed sale of securities
• 03.04.2026 - 144 Report of proposed sale of securities
• 03.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.02.2026 - 144 Report of proposed sale of securities
• 02.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.23.2026 - 144 Report of proposed sale of securities
• 02.20.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership